Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
Provided By GlobeNewswire
Last update: Jul 16, 2024
Agreement enhances Company’s intellectual property portfolio
SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14. Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs.
Read more at globenewswire.com0.6214
+0.04 (+6.94%)
Find more stocks in the Stock Screener
SILO Latest News and Analysis
17 hours ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
5 days ago - ChartmillThese stocks are moving in today's pre-market sessionThe US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
5 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
